Go Pro
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
$3.43
-2.3%		$3.81
$1.69
▼
$5.17
$431.82M2.941.99 million shs1.49 million shs
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
$2.74
+1.5%		$2.96
$1.66
▼
$4.54
$414.67M2.092.68 million shs1.69 million shs
HilleVax, Inc. stock logo
HLVX
HilleVax
$2.09
$2.09
$1.77
▼
$2.17
$104.79M0.77532,880 shsN/A
Rezolute, Inc. stock logo
RZLT
Rezolute
$4.25
+0.7%		$4.73
$1.07
▼
$11.46
$406.35M0.61.36 million shs828,018 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
-2.28%-8.78%-19.10%-10.68%+28.95%
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
+1.48%-15.17%-2.84%+16.10%+1.86%
HilleVax, Inc. stock logo
HLVX
HilleVax
0.00%0.00%0.00%0.00%0.00%
Rezolute, Inc. stock logo
RZLT
Rezolute
+0.71%-7.21%-7.61%-7.00%-44.73%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
$3.43
-2.3%		$3.81
$1.69
▼
$5.17
$431.82M2.941.99 million shs1.49 million shs
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
$2.74
+1.5%		$2.96
$1.66
▼
$4.54
$414.67M2.092.68 million shs1.69 million shs
HilleVax, Inc. stock logo
HLVX
HilleVax
$2.09
$2.09
$1.77
▼
$2.17
$104.79M0.77532,880 shsN/A
Rezolute, Inc. stock logo
RZLT
Rezolute
$4.25
+0.7%		$4.73
$1.07
▼
$11.46
$406.35M0.61.36 million shs828,018 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
-2.28%-8.78%-19.10%-10.68%+28.95%
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
+1.48%-15.17%-2.84%+16.10%+1.86%
HilleVax, Inc. stock logo
HLVX
HilleVax
0.00%0.00%0.00%0.00%0.00%
Rezolute, Inc. stock logo
RZLT
Rezolute
+0.71%-7.21%-7.61%-7.00%-44.73%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
2.60
Moderate Buy$7.67123.52% Upside
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
2.60
Moderate Buy$6.00118.98% Upside
HilleVax, Inc. stock logo
HLVX
HilleVax
0.00
N/AN/AN/A
Rezolute, Inc. stock logo
RZLT
Rezolute
2.58
Moderate Buy$9.38120.59% Upside

Current Analyst Ratings Breakdown

Latest HLVX, CCCC, EDIT, and RZLT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/18/2026
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
LADENBURG THALM/SH SH logo
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$6.00
8/14/2026
Rezolute, Inc. stock logo
RZLT
Rezolute
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
8/11/2026
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/30/2026
Rezolute, Inc. stock logo
RZLT
Rezolute
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
7/17/2026
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/17/2026
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
Rezolute, Inc. stock logo
RZLT
Rezolute
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/16/2026
Rezolute, Inc. stock logo
RZLT
Rezolute
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Strong Sell
6/15/2026
Rezolute, Inc. stock logo
RZLT
Rezolute
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$6.00 ➝ $11.00
(Data available from 9/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
$35.95M11.74N/AN/A$2.65 per share1.29
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
$40.52M10.39N/AN/A$0.28 per share9.79
HilleVax, Inc. stock logo
HLVX
HilleVax
N/AN/AN/AN/A$3.10 per shareN/A
Rezolute, Inc. stock logo
RZLT
Rezolute
N/AN/AN/AN/A$1.86 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
-$104.99M-$1.00N/AN/AN/A-289.44%-45.45%-30.90%11/5/2026 (Estimated)
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
-$160.06M-$0.75N/AN/AN/A-157.32%-196.63%-38.17%11/9/2026 (Estimated)
HilleVax, Inc. stock logo
HLVX
HilleVax
-$147.27M-$1.43N/AN/AN/AN/A-34.29%-28.50%N/A
Rezolute, Inc. stock logo
RZLT
Rezolute
-$74.41M-$0.82N/AN/AN/AN/A-58.82%-54.48%9/16/2026 (Estimated)

Latest HLVX, CCCC, EDIT, and RZLT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/16/2026Q4 2026
Rezolute, Inc. stock logo
RZLT
Rezolute
-$0.1479N/AN/AN/AN/AN/A
8/11/2026Q2 2026
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
-$0.2264-$0.18+$0.0464-$0.18$4.00 million$6.64 million
8/5/2026Q2 2026
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
-$0.2705-$0.15+$0.1205-$0.15$2.85 million$11.89 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
N/AN/AN/AN/AN/A
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
N/AN/AN/AN/AN/A
HilleVax, Inc. stock logo
HLVX
HilleVax
N/AN/AN/AN/AN/A
Rezolute, Inc. stock logo
RZLT
Rezolute
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
N/A
5.45
5.45
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
N/A
3.19
3.19
HilleVax, Inc. stock logo
HLVX
HilleVax
N/A
26.39
26.39
Rezolute, Inc. stock logo
RZLT
Rezolute
N/A
15.84
15.84

Institutional Ownership

CompanyInstitutional Ownership
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
78.81%
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
71.90%
HilleVax, Inc. stock logo
HLVX
HilleVax
86.42%
Rezolute, Inc. stock logo
RZLT
Rezolute
82.97%

Insider Ownership

CompanyInsider Ownership
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
5.60%
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
3.10%
HilleVax, Inc. stock logo
HLVX
HilleVax
24.90%
Rezolute, Inc. stock logo
RZLT
Rezolute
14.78%
CompanyEmployeesShares OutstandingFree FloatOptionable
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
104123.03 million116.14 millionOptionable
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
87153.58 million148.82 millionOptionable
HilleVax, Inc. stock logo
HLVX
HilleVax
2050.14 million37.66 millionNot Optionable
Rezolute, Inc. stock logo
RZLT
Rezolute
7196.29 million82.06 millionOptionable

Recent News About These Companies

Rezolute, Inc. (NASDAQ:RZLT) Given Consensus Rating of "Moderate Buy" by Analysts
September 13 at 4:28 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-rezolute-inc-nasdaq-rzlt-given-consensus-rating-of-moderate-buy-by-analysts-2026-09-13/
Rezolute: Initiating At Sell Despite Attempts To Rescue Ersodetug Following sunRIZE Upset
September 10, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4945147-rezolute-initiating-at-sell-despite-attempts-to-rescue-ersodetug-following-sunrize-upset
Rezolute Says FDA Still Reviewing Ersodetug Data From Phase 3 Congenital Hyperinsulinism Study
September 9, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/rezolute-says-fda-still-reviewing-123003547.html
Rezolute says late-stage trial data for lead asset remains under FDA review
September 9, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4641321-rezolute-drops-regulatory-update-lead-asset
Rezolute FDA Review Continues After Phase 3 sunRIZE Study Missed Primary Endpoint
September 9, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/rezolute-fda-review-continues-phase-144325702.html
Rezolute, Inc. (RZLT) Interactive Stock Chart - Yahoo Finance
September 9, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/quote/RZLT/chart/
Rezolute, Inc. (RZLT) Interactive Stock Chart - Yahoo Finance
September 9, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/quote/RZLT/chart/
Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism
September 9, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/09/3358488/0/en/rezolute-provides-update-on-fda-review-of-its-phase-3-sunrize-study-results-in-congenital-hyperinsulinism.html
Rezolute (RZLT) Projected to Release Earnings on Wednesday
September 9, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31011733
Rezolute (RZLT) Projected to Announce Earnings on Wednesday
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/upcoming-rezolute-rzlt-projected-to-announce-earnings-on-wednesday-2026-09-09/
Rezolute to Participate in Upcoming Investor Conferences
September 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/02/3355017/0/en/rezolute-to-participate-in-upcoming-investor-conferences.html
Rezolute Shares to Show Strength Towards Upcoming Ersodetug Catalysts, Wedbush Says
August 25, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/rezolute-shares-show-strength-towards-152056560.html
Rezolute, Inc. $RZLT Shares Sold by Bank of America Corp DE
August 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-rezolute-inc-rzlt-shares-sold-by-bank-of-america-corp-de-2026-08-25/
Rezolute, Inc. (NASDAQ:RZLT) Given Average Rating of "Moderate Buy" by Brokerages
August 19, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/rezolute-inc-nasdaqrzlt-given-average-rating-of-moderate-buy-by-brokerages-2026-08-19/
Bank of New York Mellon Corp Sells 481,913 Shares of Rezolute, Inc. $RZLT
August 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-new-york-mellon-corp-sells-481913-shares-of-rezolute-inc-rzlt-2026-08-17/
Analysts Offer Insights on Healthcare Companies: Rezolute (RZLT) and Boston Scientific (BSX)
July 30, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/RZLT/pressreleases/3559521/analysts-offer-insights-on-healthcare-companies-rezolute-rzlt-and-boston-scientific-bsx/
Rezolute to Participate in the BTIG Virtual Biotechnology Conference
July 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/21/3330330/0/en/rezolute-to-participate-in-the-btig-virtual-biotechnology-conference.html
Rezolute Inc.
June 29, 2026  |  marketwatch.comhttps://www.marketwatch.com/investing/stock/rzlt/financials/cash-flow
FDA Grants Orphan Drug Designation to Rezolute's Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
June 25, 2026  |  stockhouse.comhttps://stockhouse.com/news/press-releases/2024/12/03/fda-grants-orphan-drug-designation-to-rezolute-s-ersodetug-rz358-for-the
Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society
June 17, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/17/3313313/0/en/rezolute-highlights-results-presented-from-natural-history-outcomes-studies-and-its-ersodetug-clinical-program-in-hyperinsulinism-at-annual-meeting-of-the-endocrine-society.html
Analysts Offer Insights on Healthcare Companies: Rezolute (RZLT) and Vericel (VCEL)
June 12, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/VCEL/pressreleases/2413956/analysts-offer-insights-on-healthcare-companies-rezolute-rzlt-and-vericel-vcel/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Illuminated Pathward logo displayed on a wall in a corporate office reception area with glass doors.
Pathward’s Credit Scare Tests Its Comeback Story
By Peter Frank | August 25, 2026
OneMain Financial logo displayed over a blurred background of a house, car, and car keys on a table.
OneMain’s Yield Comes With a Catch
By Peter Frank | August 30, 2026
A dark green Rivian electric pickup truck parked in front of a building displaying the Rivian logo, with mountains in the background.
What Rising Delivery Forecasts Say About Rivian's Stock Prospects
By Sam Quirke | August 24, 2026
Scientist handles blood sample in lab, symbolizing early cancer detection.
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It
By Bridget Bennett | September 6, 2026
Intuit logo displayed over a desk with a laptop, coffee mug, notebook, plant, and financial chart printout.
Intuit’s Earnings Reset May Be More Pivot Than Plunge
By Jeffrey Neal Johnson | August 28, 2026
C4 Therapeutics stock logo

C4 Therapeutics NASDAQ:CCCC

$3.43 -0.08 (-2.28%)
Closing price 09/14/2026 04:00 PM Eastern
Extended Trading
$3.45 +0.02 (+0.55%)
As of 09/14/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Editas Medicine stock logo

Editas Medicine NASDAQ:EDIT

$2.74 +0.04 (+1.48%)
Closing price 09/14/2026 04:00 PM Eastern
Extended Trading
$2.74 0.00 (-0.07%)
As of 09/14/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

HilleVax stock logo

HilleVax NASDAQ:HLVX

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

Rezolute stock logo

Rezolute NASDAQ:RZLT

$4.25 +0.03 (+0.71%)
Closing price 09/14/2026 04:00 PM Eastern
Extended Trading
$4.20 -0.05 (-1.18%)
As of 09/14/2026 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas